The Federal Circuit has been approached to deliver judgment on a matter concerning Allergan and Sandoz, the generic-drug arm of Novartis. A $39 million patent-related verdict previously in favor of Allergan, the company responsible for a well-known eyebrow growth medication, has been called into question by Sandoz. The catalyst for this dispute is said to be a patent relation to another one, discarded by the very same appeals court nearly ten years ago.
This legal scenario involves past history with the appeals court, where a different patent associated with this case was dismissed. The implications of such a case might have a significant influence on the current and future relationships between brand-name pharmaceutical companies and their generic equivalents.
For a more detailed examination of this case, please refer to the article on the Law360 website.